{"title":"Serum Albumin as a Prognostic Marker for Overall Survival in Acute Myeloid Leukemia","link":"https://www.preprints.org/manuscript/202406.0630/v1","date":1718087624000,"content":"In this retrospective analysis, we examined the prognostic value of serum albumin at diagnosis prior to any therapy in a cohort of patients with acute myeloid leukemia (AML) irrespective of treatment modality.\nData were collected retrospectively in a cohort of 257 AML patients who received treatment between 2002 to 2019. The cohort included patients who received conventional 7+3 induction, patients who were not candidates for induction receiving lower-intensity chemotherapy or targeted therapy, and patients who were placed on clinical trials. Patients were classified into two groups, by serum albumin level at presentation, normal albumin (â‰¥3.5 g/dL) and hypoalbuminemia [HA](","author":"","siteTitle":"Preprints.org - The Multidisciplinary Preprint Platform","siteHash":"abac34b0506002eba4392ac15186820b9b5d7a0f2e5fce3a3511408258fb1a7e","entryHash":"0b0b81888df4bd91709a2a56e9db7fca674f58af06bd515ed12adcd71ced6a81","category":"Interdisciplinary"}